Company intelligence / Profile preview
Vaccinex, Inc.
Rochester, New York, United Statesvaccinex.com ↗
- Ownership
- Public · VCNX
- Employees
- ~32
- Development stage
- Phase 2
01
Overview
Vaccinex's lead candidate pepinemab is a humanized monoclonal antibody targeting SEMA4D. In oncology trials such as KEYNOTE-B84 with Merck’s pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), interim data showed approximately double the objective response rate and progression-free survival in patients with low PD-L1 expression compared to historical controls. Pepinemab has also shown potential in neurodegenerative diseases like Alzheimer’s and Huntington’s disease. Final data from ongoing studies are expected at upcoming conferences.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Monoclonal antibodies (mAbs)Fusion proteinsAntibody discovery platforms
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Merck Sharp & Dohme Corp.Ares Trading S.A.Children’s Hospital of PhiladelphiaEmory UniversityHuntington Study GroupH. Lee Moffitt Cancer Center & Research Institute Inc.Catalent Pharma Solutions LLC.Surface Oncology Inc.
04
Financials
- Market cap
- $2.8M
- Total revenue
- $213K
- Enterprise value
- $1.7M
Beyond the preview
Go deeper on Vaccinex, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaccinex, Inc..